Innoviva (INVA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

INVA Stock Forecast

Innoviva stock forecast is as follows: an average price target of $13.00 (represents a -27.13% downside from INVA’s last price of $17.84) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

INVA Price Target

The average price target for Innoviva (INVA) is $13.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $13.00. This represents a potential -27.13% downside from INVA's last price of $17.84.

INVA Analyst Ratings

Buy

According to 2 Wall Street analysts, Innoviva's rating consensus is 'Buy'. The analyst rating breakdown for INVA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).

Innoviva Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Aug 08, 2022		Morgan Stanley	$13.00	$14.72	-11.68%	-27.13%
Jul 15, 2022		Morgan Stanley	$12.00	$14.37	-16.49%	-32.74%

The latest Innoviva stock forecast, released on Aug 08, 2022 by Morgan Stanley company, set a price target of $13.00, which represents a -11.68% decrease from the stock price at the time of the forecast ($14.72), and a -27.13% decrease from INVA last price ($17.84).

Innoviva Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$17.84	$17.84	$17.84
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Innoviva stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Innoviva's last price of $17.84. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Jun 18, 2024	Cantor Fitzgerald		Overweight	Initialise
Aug 08, 2022	Morgan Stanley	Underweight	Underweight	Hold
Jul 15, 2022	Morgan Stanley	Underweight	Underweight	Hold
Feb 23, 2022	Morgan Stanley	Underweight	Underweight	Hold

Innoviva's last stock rating was published by Cantor Fitzgerald on Jun 18, 2024. The company Initialise its INVA rating from "null" to "Overweight".

Innoviva Financial Forecast

Innoviva Revenue Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
Revenue	-	-	-	-	-	-	-	$85.84M	$67.26M	$80.99M	$76.37M	$65.80M	$67.26M	$108.22M	$90.06M	$100.81M	$90.48M	$88.69M	$78.95M	$78.68M	$75.97M	$65.75M	$64.11M	$55.18M	$52.38M	$40.49M	$24.18M	$6.90M	$165.00K	$1.34M
Avg Forecast	$88.39M	$86.86M	$80.42M	$86.80M	$76.91M	$74.69M	$68.00M	$75.52M	$75.66M	$67.92M	$62.01M	$58.85M	$62.60M	$214.78M	$86.40M	$111.23M	$75.30M	$71.10M	$68.30M	$60.80M	$71.80M	$61.70M	$68.90M	$54.50M	$102.86M	$72.90M	$60.50M	$6.13M	$683.87K	$1.30M
High Forecast	$91.45M	$89.88M	$83.20M	$92.59M	$76.91M	$77.28M	$70.36M	$78.13M	$78.28M	$70.27M	$64.16M	$60.89M	$62.60M	$214.78M	$86.40M	$133.48M	$75.30M	$71.10M	$68.30M	$60.80M	$71.80M	$61.70M	$68.90M	$54.50M	$123.43M	$87.48M	$72.60M	$7.36M	$820.64K	$1.56M
Low Forecast	$85.33M	$83.85M	$77.63M	$81.00M	$76.91M	$72.10M	$65.65M	$72.90M	$73.03M	$65.56M	$59.86M	$56.81M	$62.60M	$214.78M	$86.40M	$88.99M	$75.30M	$71.10M	$68.30M	$60.80M	$71.80M	$61.70M	$68.90M	$54.50M	$82.29M	$58.32M	$48.40M	$4.91M	$547.10K	$1.04M
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	9	9	20	10	10	10	10	9	9	9	9	20	10	7	14	12	18
Surprise %	-	-	-	-	-	-	-	1.14%	0.89%	1.19%	1.23%	1.12%	1.07%	0.50%	1.04%	0.91%	1.20%	1.25%	1.16%	1.29%	1.06%	1.07%	0.93%	1.01%	0.51%	0.56%	0.40%	1.12%	0.24%	1.03%

Innoviva's average Quarter revenue forecast for Mar 24 based on 1 analysts is $68.00M, with a low forecast of $65.65M, and a high forecast of $70.36M. INVA's average Quarter revenue forecast represents a -20.78% decrease compared to the company's last Quarter revenue of $85.84M (Dec 23).

Innoviva EBITDA Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	9	9	20	10	10	10	10	9	9	9	9	20	10	7	14	12	18
EBITDA	-	-	-	-	-	-	-	$44.03M	$100.53M	$19.17M	$51.54M	$28.82M	$30.11M	$86.34M	$77.80M	$122.48M	$77.75M	$45.15M	$104.75M	$89.35M	$66.52M	$58.38M	$56.38M	$50.45M	$40.71M	$33.12M	$21.07M	$5.52M	$-62.66M	$-31.49M
Avg Forecast	$84.40M	$82.95M	$76.79M	$82.88M	$73.45M	$71.32M	$42.48M	$72.11M	$72.24M	$64.85M	$38.62M	$18.85M	$49.90M	$171.19M	$35.11M	$88.66M	$60.02M	$56.67M	$54.44M	$48.46M	$57.23M	$49.18M	$54.92M	$43.44M	$54.61M	$43.06M	$30.35M	$4.83M	$-52.02M	$-31.49M
High Forecast	$87.33M	$85.82M	$79.45M	$88.42M	$73.45M	$73.79M	$50.97M	$74.61M	$74.75M	$67.10M	$46.34M	$22.62M	$49.90M	$171.19M	$42.13M	$106.39M	$60.02M	$56.67M	$54.44M	$48.46M	$57.23M	$49.18M	$54.92M	$43.44M	$65.53M	$51.67M	$36.42M	$5.80M	$-41.62M	$-25.19M
Low Forecast	$81.48M	$80.07M	$74.13M	$77.35M	$73.44M	$68.85M	$33.98M	$69.61M	$69.74M	$62.61M	$30.89M	$15.08M	$49.90M	$171.19M	$28.08M	$70.93M	$60.02M	$56.67M	$54.44M	$48.46M	$57.23M	$49.18M	$54.92M	$43.44M	$43.69M	$34.45M	$24.28M	$3.87M	$-62.42M	$-37.79M
Surprise %	-	-	-	-	-	-	-	0.61%	1.39%	0.30%	1.33%	1.53%	0.60%	0.50%	2.22%	1.38%	1.30%	0.80%	1.92%	1.84%	1.16%	1.19%	1.03%	1.16%	0.75%	0.77%	0.69%	1.14%	1.20%	1.00%

1 analysts predict INVA's average Quarter EBITDA for Mar 24 to be $42.48M, with a high of $50.97M and a low of $33.98M. This is -3.54% lower than Innoviva's previous annual EBITDA (Dec 23) of $44.03M.

Innoviva Net Income Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	9	9	20	10	10	10	10	9	9	9	9	20	10	7	14	12	18
Net Income	-	-	-	-	-	-	-	$61.53M	$82.05M	$1.28M	$34.87M	$-68.31M	$265.52M	$21.37M	$37.86M	$88.95M	$75.02M	$41.62M	$76.84M	$65.44M	$45.95M	$39.81M	$37.74M	$33.79M	$19.22M	$4.35M	$-8.66M	$-23.37M	$-69.16M	$-41.33M
Avg Forecast	$27.07M	$25.81M	$23.92M	$23.29M	$16.68M	$14.79M	$22.99M	$14.48M	$17.00M	$16.37M	$20.90M	$7.49M	$95.66M	$91.71M	$19.00M	$98.15M	$25.01M	$26.26M	$20.01M	$57.66M	$30.95M	$22.82M	$26.57M	$38.48M	$39.68M	$21.90M	$6.39M	$-9.33M	$-56.21M	$-37.36M
High Forecast	$28.29M	$26.97M	$25.00M	$25.81M	$17.43M	$15.46M	$27.59M	$15.13M	$17.76M	$17.11M	$25.08M	$8.99M	$95.66M	$91.71M	$22.80M	$117.78M	$25.01M	$26.26M	$20.01M	$69.19M	$30.95M	$22.82M	$26.57M	$46.18M	$47.62M	$26.28M	$7.66M	$-7.47M	$-44.97M	$-29.89M
Low Forecast	$25.85M	$24.65M	$22.84M	$20.77M	$15.93M	$14.13M	$18.39M	$13.83M	$16.23M	$15.63M	$16.72M	$6.00M	$95.66M	$91.71M	$15.20M	$78.52M	$25.01M	$26.26M	$20.01M	$46.13M	$30.95M	$22.82M	$26.57M	$30.79M	$31.75M	$17.52M	$5.11M	$-11.20M	$-67.45M	$-44.83M
Surprise %	-	-	-	-	-	-	-	4.25%	4.83%	0.08%	1.67%	-9.12%	2.78%	0.23%	1.99%	0.91%	3.00%	1.58%	3.84%	1.13%	1.48%	1.74%	1.42%	0.88%	0.48%	0.20%	-1.36%	2.50%	1.23%	1.11%

Innoviva's average Quarter net income forecast for Mar 24 is $22.99M, with a range of $18.39M to $27.59M. INVA's average Quarter net income forecast represents a -62.64% decrease compared to the company's last Quarter net income of $61.53M (Dec 23).

Innoviva SG&A Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	9	9	20	10	10	10	10	9	9	9	9	20	10	7	14	12	18
SG&A	-	-	-	-	-	-	-	$26.32M	$28.64M	$23.54M	$19.73M	$17.39M	$27.81M	$11.78M	$6.49M	$4.23M	$5.47M	$3.25M	$2.60M	$2.56M	$2.33M	$4.96M	$4.35M	$3.02M	$11.69M	$10.79M	$6.25M	$5.44M	$22.83M	$8.31M
Avg Forecast	$11.43M	$11.24M	$10.40M	$11.23M	$9.95M	$9.66M	$9.46M	$9.77M	$9.79M	$8.79M	$8.60M	$2.26M	$7.93M	$27.19M	$7.82M	$4.67M	$9.53M	$9.00M	$8.65M	$2.26M	$9.09M	$7.81M	$8.72M	$3.43M	$15.68M	$14.03M	$9.00M	$4.76M	$86.58K	$164.58K
High Forecast	$11.83M	$11.63M	$10.76M	$11.98M	$9.95M	$10.00M	$11.35M	$10.11M	$10.13M	$9.09M	$10.32M	$2.71M	$7.93M	$27.19M	$9.38M	$5.60M	$9.53M	$9.00M	$8.65M	$2.71M	$9.09M	$7.81M	$8.72M	$4.12M	$18.81M	$16.84M	$10.80M	$5.71M	$103.89K	$197.50K
Low Forecast	$11.04M	$10.85M	$10.04M	$10.48M	$9.95M	$9.33M	$7.57M	$9.43M	$9.45M	$8.48M	$6.88M	$1.80M	$7.93M	$27.19M	$6.26M	$3.73M	$9.53M	$9.00M	$8.65M	$1.81M	$9.09M	$7.81M	$8.72M	$2.75M	$12.54M	$11.23M	$7.20M	$3.81M	$69.26K	$131.66K
Surprise %	-	-	-	-	-	-	-	2.69%	2.93%	2.68%	2.29%	7.71%	3.51%	0.43%	0.83%	0.91%	0.57%	0.36%	0.30%	1.13%	0.26%	0.64%	0.50%	0.88%	0.75%	0.77%	0.69%	1.14%	263.74%	50.52%

Innoviva's average Quarter SG&A projection for Mar 24 is $9.46M, based on 1 Wall Street analysts, with a range of $7.57M to $11.35M. The forecast indicates a -64.05% fall compared to INVA last annual SG&A of $26.32M (Dec 23).

Innoviva EPS Forecast

	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Jun 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16	Mar 15	Mar 14	Mar 13
# Analysts	1	1	1	2	1	1	1	1	1	1	1	1	1	9	9	20	10	10	10	10	9	9	9	9	20	10	7	14	12	18
EPS	-	-	-	-	-	-	-	$0.72	$1.26	$0.02	$0.51	$-0.98	$3.81	$0.31	$0.54	$1.01	$0.74	$0.41	$0.76	$0.65	$0.45	$0.39	$0.37	$0.33	$0.19	$0.04	$-0.08	$-0.20	$-0.63	$-0.43
Avg Forecast	$0.43	$0.41	$0.38	$0.37	$0.27	$0.23	$0.17	$0.23	$0.27	$0.26	$0.23	$0.23	$1.53	$1.47	$0.44	$0.29	$0.40	$0.42	$0.32	$0.36	$0.49	$0.36	$0.42	$0.36	$0.71	$0.35	$0.14	$-0.07	$-0.44	$-0.38
High Forecast	$0.45	$0.43	$0.40	$0.41	$0.28	$0.25	$0.18	$0.24	$0.28	$0.27	$0.24	$0.24	$1.53	$1.47	$0.44	$0.29	$0.40	$0.42	$0.32	$0.36	$0.49	$0.36	$0.42	$0.36	$0.85	$0.42	$0.17	$-0.06	$-0.35	$-0.30
Low Forecast	$0.41	$0.39	$0.36	$0.33	$0.25	$0.22	$0.16	$0.22	$0.26	$0.25	$0.22	$0.21	$1.53	$1.47	$0.44	$0.29	$0.40	$0.42	$0.32	$0.36	$0.49	$0.36	$0.42	$0.36	$0.57	$0.28	$0.12	$-0.08	$-0.53	$-0.46
Surprise %	-	-	-	-	-	-	-	3.13%	4.67%	0.08%	2.22%	-4.36%	2.49%	0.21%	1.23%	3.48%	1.85%	0.98%	2.38%	1.81%	0.91%	1.07%	0.87%	0.92%	0.27%	0.12%	-0.55%	2.86%	1.43%	1.13%

According to 1 Wall Street analysts, Innoviva's projected average Quarter EPS for Mar 24 is $0.17, with a low estimate of $0.16 and a high estimate of $0.18. This represents a -76.39% decrease compared to INVA previous annual EPS of $0.72 (Dec 23).

Innoviva Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ELEV	Elevation Oncology	$0.67	$9.00	1243.28%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
PDSB	PDS Bio	$1.96	$9.00	359.18%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
FOLD	Amicus Therapeutics	$9.89	$15.00	51.67%	Buy
DNLI	Denali Therapeutics	$23.22	$35.00	50.73%	Buy
HRMY	Harmony Biosciences	$33.63	$48.00	42.73%	Buy
HOOK	HOOKIPA Pharma	$2.13	$3.00	40.85%	Buy
INCY	Incyte	$69.40	$90.11	29.84%	Buy
ARGX	argenx SE	$638.33	$558.78	-12.46%	Buy
INVA	Innoviva	$18.37	$13.00	-29.23%	Buy

INVA Forecast FAQ

Is Innoviva a good buy?

Yes, according to 2 Wall Street analysts, Innoviva (INVA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of INVA's total ratings.

What is INVA's price target?

Innoviva (INVA) average price target is $13 with a range of $13 to $13, implying a -27.13% from its last price of $17.84. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Innoviva stock go up soon?

According to Wall Street analysts' prediction for INVA stock, the company can go down by -27.13% (from the last price of $17.84 to the average price target of $13), down by -27.13% based on the highest stock price target, and down by -27.13% based on the lowest stock price target.

Can Innoviva stock reach $30?

INVA's average twelve months analyst stock price target of $13 does not support the claim that Innoviva can reach $30 in the near future.

What are Innoviva's analysts' financial forecasts?

INVA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $306.4M (high $317.14M, low $295.66M), average EBITDA is $270.12M (high $286.62M, low $253.62M), average net income is $77.76M (high $86.29M, low $69.22M), average SG&A $40.3M (high $43.28M, low $37.33M), and average EPS is $1.04 (high $1.11, low $0.97).

Did the INVA's actual financial results beat the analysts' financial forecasts?

Based on Innoviva's last annual report (Dec 2023), the company's revenue was $310.46M, beating the average analysts forecast of $281.1M by 10.45%. Apple's EBITDA was $176.71M, missing the average prediction of $247.82M by -28.69%. The company's net income was $179.72M, beating the average estimation of $68.74M by 161.44%. Apple's SG&A was $98.23M, beating the average forecast of $36.94M by 165.89%. Lastly, the company's EPS was $2.07, beating the average prediction of $0.99 by 109.09%. In terms of the last quarterly report (Dec 2023), Innoviva's revenue was $85.84M, beating the average analysts' forecast of $75.52M by 13.67%. The company's EBITDA was $44.04M, missing the average prediction of $72.11M by -38.93%. Innoviva's net income was $61.53M, beating the average estimation of $14.48M by 324.98%. The company's SG&A was $26.32M, beating the average forecast of $9.77M by 169.41%. Lastly, the company's EPS was $0.72, beating the average prediction of $0.23 by 213.04%